Is therapeutic drug monitoring really helpful for managing piperacillin/tazobactam therapy in critically ill patients?

Intensive Care Med. 2022 Nov;48(11):1676-1678. doi: 10.1007/s00134-022-06830-x. Epub 2022 Aug 9.

Emmanuel Novy^{1

2}, Thomas François¹, Amandine Luc³, Elise Pape^{4

5}, Julien Scala-Bertola^{6

7}

¹ Department of Anaesthesiology, Critical Care and Peri-Operative Medicine, CHRU-Nancy, 54000, Nancy, France.
² SIMPA, Stress Immunity Pathogens Unit, EA 7300, Université de Lorraine, 54000, Nancy, France.
³ DRCI, MPI department, Methodology, Data Management and Statistic Unit, CHRU-Nancy, 54000, Nancy, France.
⁴ Service de Pharmacologie Clinique et Toxicologie, Université de Lorraine, CHRU-Nancy, 54000, Nancy, France.
⁵ Université de Lorraine, CNRS, IMoPA, 54000, Nancy, France.
⁶ Service de Pharmacologie Clinique et Toxicologie, Université de Lorraine, CHRU-Nancy, 54000, Nancy, France. j.scala-bertola@chru-nancy.fr.
⁷ Université de Lorraine, CNRS, IMoPA, 54000, Nancy, France. j.scala-bertola@chru-nancy.fr.

No abstract available

Publication types